Alembic Pharmaceuticals gets FDA final approval for Desonide Cream, 0.05%

TAGS

Alembic Pharmaceuticals has secured final approval for its abbreviated new drug application (ANDA) of Desonide Cream, 0.05% from the Food and Drug Administration (FDA).

The ANDA for the generic version of Padagis US’ Desonide Cream, 0.05% was filed by Aleor Dermaceuticals, which was merged with Alembic Pharmaceuticals.

The approved product is a low potency corticosteroid to be used for relieving inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

According to IQVIA, Desonide Cream, 0.05% has an estimated market size of $12 million for 12 months ending September 2022.

Alembic Pharmaceuticals, which is an -based company, has so far bagged 178 ANDA approvals from the FDA, of which 155 are final approvals and the rest are tentative approvals.

CATEGORIES
TAGS
Share This

COMMENTS

Wordpress (0)